Evidence summary
What the research actually says
66Evidence confidence
Human RCT evidence31 randomized controlled trials · 4 meta-analyses / systematic reviews
Moderate human trial data (migraine, dizziness); strong mechanistic data
Gastrodin, the primary active compound, crosses the blood-brain barrier and has demonstrated neuroprotective, anti-neuroinflammatory, and neurotrophic effects in animal and cell models. Human trials show moderate evidence for migraine prevention and mild cognitive support.
48registered clinical trials reference this intervention 2selected from 312+ PubMed papers (longevity / aging angle) Key active: Gastrodin (p-hydroxybenzyl alcohol glucoside).
According to PubMed and ClinicalTrials.gov: trial counts from ClinicalTrials.gov, peer-reviewed literature from PubMed. Counts auto-refresh weekly; last checked 2026-06-14. They include trials across many endpoints, not only longevity.
Informational only — not medical advice, a treatment claim, or a substitute for a qualified clinician. Evidence strength varies; we show mixed and null results on purpose.